Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
giovedì, ottobre 22
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Korro Bio Inc
KRRO
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$9.62
0.33
3.55%
Ult. Agg.: Oct 22, 8:21 AM
$9.62
0.33
3.55%
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Opzioni
Rapporto azionario
Privacy Manager
Korro Bio Financials
Korro Bio (KRRO) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Korro Bio Q2 EPS $(1.07) Beats $(1.31) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.07) per share which beat the analyst consensus estimate of $(1.31) by 18.32 percent. This is a 60.95 percent increase over losses of $(2.74) per share from the
Benzinga Newsdesk
PRO
Korro Bio Q1 EPS $(1.69) Beats $(2.17) Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(1.69) per share which beat the analyst consensus estimate of $(2.17) by 22.12 percent. This is a 32.13 percent increase over losses of $(2.49) per share from the
Benzinga Newsdesk
Korro Bio Stock Gains After Tough 2025 - New Drug Candidate, Analyst Upgrades Boost Outlook
Korro Bio stock rises after earnings as analysts upgrade outlook, highlight new drug candidate, and long-term growth plans.
Vandana Singh
PRO
Korro Bio Q4 EPS $(5.32) Misses $(2.05) Estimate, Sales $1.290M Beat $670.000K Estimate
Korro Bio (NASDAQ:KRRO) reported quarterly losses of $(5.32) per share which missed the analyst consensus estimate of $(2.05) by 159.39 percent. This is a 135.4 percent decrease over losses of $(2.26) per share from the
Benzinga Newsdesk
Dow Dips Over 400 Points; JD.com Posts Upbeat Q3 Results
Avi Kapoor
Nasdaq Down Over 150 Points; Disney Shares Fall After Q4 Results
Avi Kapoor
